Floatz logo

Granisetron

Nausea

University of Southern CaliforniaSmall moleculePhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Nausea cohort.

Asset / SponsorPhaseRating
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Rush University Medical Center
Phase 4A
DEXAMETHASONE
The Hong Kong Polytechnic University
Phase 4BBB
Zofran
University of South Florida
Phase 4BBB
Benadryl
United States Naval Medical Center, Portsmouth
Phase 4BB
FENTANYL
United States Naval Medical Center, Portsmouth
Phase 4BB

View all 32 →

Same molecule, other indications

Granisetron is also rated in:

cancer of unknown primary siteDormant
BB
Indicative ·
71 / 100
View asset →
myofascial pain syndromeDormant
BB
Indicative ·
69 / 100
View asset →
temporomandibular joint disorderDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →